Experience

Neurophth Therapeutics / 纽福斯生物科技有限公司

• China
• Biotechnology Research
• 1 - 100 Employee

• Chief Financial Officer

  • Nov 2021 - Present

  Led Company's c.USD100m serie C+ financing Led Company's c.USD100m serie C+ financing



Ascentage Pharma

• China
• Biotechnology Research
• 1 - 100 Employee

• Chief Financial Officer

  • Aug 2019 - Nov 2021

  - Led Company’s Hong Kong IPO and subsequent equity financing that raised USD290m in total - Led Company’s Hong Kong IPO and subsequent equity financing that raised USD290m in total



China Merchants Securities Co., Ltd.

• China
• Financial Services
• 500 - 600 Employee

• Director, China healthcare equity research

  • Dec 2016 - Aug 2019

  - Covered Sino Biopharm, CSPC, CR Pharma, Shanghai Pharma, CBPO, Luye, 3S Bio, SSY, HEC, Consun Pharma, Universal Medical, CR Phoenix, New Century Healthcare - Lead analyst in the IPO of Wuxi Biologics, Innovent, Cstone and Jinxin Fertility - Ranked Asiamoney China H-share No 2 (2019) and No 3 (2018), Hong Kong No 2 (2017, 2018, 2019); Thomson Reuters Best Stock-picker No 2 (2018) - Covered Sino Biopharm, CSPC, CR Pharma, Shanghai Pharma, CBPO, Luye, 3S Bio, SSY, HEC, Consun Pharma, Universal Medical, CR Phoenix, New Century Healthcare - Lead analyst in the IPO of Wuxi Biologics, Innovent, Cstone and Jinxin Fertility - Ranked Asiamoney China H-share No 2 (2019) and No 3 (2018), Hong Kong No 2 (2017, 2018, 2019); Thomson Reuters Best Stock-picker No 2 (2018)



BNP Paribas

• France
• Banking
• 700 & Above Employee

• Associate director, equity analyst (Healthcare)

  • Apr 2015 - Dec 2016

  - Covered China healthcare sector –CSPC, Sino Biopharm, Luye, Phoenix, Fosun Pharma, China TCM, Livzon, HEC Pharma - Lead analyst in Rici Healthcare IPO - Covered China healthcare sector –CSPC, Sino Biopharm, Luye, Phoenix, Fosun Pharma, China TCM, Livzon, HEC Pharma - Lead analyst in Rici Healthcare IPO



Standard Chartered Bank

• United Kingdom
• Banking
• 700 & Above Employee

• Equity analyst (Healthcare, Small/Mid-cap Companies)

  • Jun 2013 - Feb 2015

  - Initiated and covered both A share and H share listed companies in China healthcare sector – Sihuan, CSPC, iKang, Aier Eye, Phoenix, United Lab, Lee’s Pharm - Responsible for researching Emerging Companies (companies with sub USD3bn market cap) in China and Hong Kong – Haier, Man Wah, GOME, Haitian, Johnson Electric, TCL - Lead analyst in Ozner IPO; assisted in BDT IPO - Initiated and covered both A share and H share listed companies in China healthcare sector – Sihuan, CSPC, iKang, Aier Eye, Phoenix, United Lab, Lee’s Pharm - Responsible for researching Emerging Companies (companies with sub USD3bn market cap) in China and Hong Kong – Haier, Man Wah, GOME, Haitian, Johnson Electric, TCL - Lead analyst in Ozner IPO; assisted in BDT IPO



Exane

• France
• Investment Banking
• 400 - 500 Employee

• Strategist

  • Jan 2011 - Oct 2012

  - Initiated and developed equity strategy product with a focus on China with an average readership of 350 institutional clients, covering macro, thematic research and event-driven trade ideas - Contributed to cross-sector research with Capital Goods (Extel Top 5 team), Chemical, Building Materials, Auto and Luxury team

• Equity analyst (Building Materails, Metals and Mining)

  • Jan 2007 - Dec 2010

  - Covered equities in European Building Materials & Construction sector (Extel No 1 team)- Developed commodity strategies in Metal and Mining (Extel Top 3 team)- Published several well-recognised fundamental sector notes on the cement, steel and aluminium industries in China and India- Performed benchmark analysis on Asian peers with Capital Goods (Extel Top 5 team), Chemicals, and Building Materials



Standard Chartered Bank

• United Kingdom
• Banking
• 700 & Above Employee

• Credit research manager

  • Jan 2005 - Jul 2005

  - Responsible for credit research of over 100 mid-market groups in Chinese Steel, Pharma, Retail and Real Estate sectors - Directed credit skills seminars and developed case studies for branch sales - Responsible for credit research of over 100 mid-market groups in Chinese Steel, Pharma, Retail and Real Estate sectors - Directed credit skills seminars and developed case studies for branch sales



PwC

• Professional Services
• 700 & Above Employee

• Senior advisory associate

  • Aug 2000 - Dec 2004

  - Supervised the review of over 1,000 non-performing loans and drafted the credit sections of IFRS financial statements for Bank of China and Bank of Communications - Statutory and IPO audit for 40 Chinese and multinational companies and banks including listed firms in NYSE, HKSE and SGX - Conducted benchmarking for China’s banking, telecom, oil and gas and transportation sectors - Supervised the review of over 1,000 non-performing loans and drafted the credit sections of IFRS financial statements for Bank of China and Bank of Communications - Statutory and IPO audit for 40 Chinese and multinational companies and banks including listed firms in NYSE, HKSE and SGX - Conducted benchmarking for China’s banking, telecom, oil and gas and transportation sectors